There are currently 124 active clinical trials seeking participants for Pancreatic Cancer research studies. The states with the highest number of trials for Pancreatic Cancer participants are California, New York, Illinois and Texas.
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
NCT06582849
Recruiting
This is a prospective single-arm study of an enhanced assistance intervention for patients with unmet essential needs undergoing \>10 fractions of radiotherapy comparing delay-free completion of radiotherapy in study participants to historic controls.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer, Lymphoma, Salivary Gland Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Small Intestine Cancer, Stomach Cancer, Urinary Bladder Cancer, Anal Cancer, Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Kidney Cancer, Penile Cancer, Skin Cancer, Testicular Cancer, Thyroid Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
Register for Updates
Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
NCT04588025
Recruiting
The goal of this study is to investigate whether the therapeutic response of pancreatic tumors can be accurately assessed using quantitative DCE-MRI, when the inter/intra-scanner variability is reduced using the Point-of-care Portable Perfusion Phantom, P4. The intra-scanner variability over time leads to errors in therapy monitoring, while the inter-scanner variability impedes the comparison of data among institutes. The P4 is small enough to be imaged concurrently in the bore of a standard MRI... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
10/07/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +1 locations
Conditions: Pancreatic Cancer
Register for Updates
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
NCT03551951
Recruiting
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2024
Locations: Harry S Truman Veterans Memorial Hospital, Columbia, Missouri
Conditions: Non Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
Register for Updates
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
NCT02838836
Recruiting
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2024
Locations: Ellis Fischel Cancer Center, University of Missouri, Columbia, Missouri
Conditions: Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
Register for Updates
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432
Recruiting
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Karmanos Cancer Center, Detroit, Michigan +7 locations
Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Register for Updates
UCSF PANC Cyst Registry
NCT04291651
Recruiting
Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are benign. Increased detection of pancreatic cysts provides an opportunity to diagnose pancreatic malignancy at an early, curable stage yet also increases the potential to over-treat clinically insignificant lesions. This presents a clinical challenge to pr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Pancreatic Cyst, Pancreatic Neoplasms, Pancreatic Cancer, Pancreatic Diseases, Pancreatic Ductal Adenocarcinoma, Mucinous Cyst, Pancreatic Intraductal Papillary Mucinous Neoplasm, Intraductal Papillary Mucinous Neoplasm
Register for Updates
Artificial Inteligence in Endoscopic Ultrasound
NCT06564571
Recruiting
The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/19/2024
Locations: Orlando Health, Orlando, Florida
Conditions: Pancreatic Cancer, Pancreas Disease, Pancreatic Cyst
Register for Updates
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
NCT05013216
Recruiting
This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant for patients who have been identified to be at risk of developing pancreatic cancer.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/06/2024
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: High Risk Cancer, Pancreatic Cancer
Register for Updates
Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma
NCT05141513
Recruiting
This study is designed to investigate the safety of intraoperative radiation therapy (IORT) in patients with localized pancreatic cancer undergoing surgical resection after neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates
Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer
NCT06205849
Recruiting
This is a phase I study of an agonistic CD40 antibody (mitazalimab) injected intratumorally at the time of surgical IRE in patients with locally advanced pancreatic cancer. Intratumoral delivery has potential to be more effective than systemic (intravenous) delivery while decreasing the systemic side effects of immunotherapy. We hypothesize that local delivery of mitazalimab at the time of IRE in patients with locally advanced pancreatic cancer will be safe, augment the immune effects of IRE, an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: UCSD Moores Cancer Center, La Jolla, California
Conditions: Pancreatic Cancer
Register for Updates
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT04150042
Recruiting
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic cancer in patients who have a deleterious or suspected deleterious BRCA1, BRCA2, or PALB2 genetic alteration. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, low-dose I.V. ethanol, vitamin B12b, and vitamin C in association with autologous hematopoietic stem cell infusion. A dose-escalation schedule will be employed fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Breast Cancer Metastatic, Breast Cancer Stage IV, Pancreatic Cancer Stage IV, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Adenocarcinoma of the Breast, PALB2 Gene Mutation
Register for Updates
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
NCT03935893
Recruiting
This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic cancer associated with one of the following cancer types: 1.) gastric/esophagogastric, 2.) colorectal, 3.) pancreatic, 4.) sarcoma, 5.) mesothelioma, 6.) neuroendocrine, 7.) squamous cell cancer, 8.) Merkle cell, 9.) mismatch repair deficient and/or microsatellite un... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/21/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Sarcoma, Mesothelioma, Neuroendocrine Tumors, Squamous Cell Cancer, Merkel Cell Carcinoma, Mismatch Repair Deficiency, Microsatellite Instability
Register for Updates